The role of activated carbon in pharma
Activated carbon has two distinct roles in pharmaceutical manufacturing. First, as a processing aid — used to decolorise API (active pharmaceutical ingredient) solutions, removing coloured impurities from the bulk drug before final crystallisation or formulation. Second, as an active ingredient — in medicinal charcoal products (activated charcoal tablets, oral suspensions, veterinary formulations) used to treat poisoning and overdose.
Why pharmacopoeial grade matters
Pharmaceutical activated carbon must meet the specifications of the relevant pharmacopoeia — BP (British Pharmacopoeia), USP (US Pharmacopoeia), or EP (European Pharmacopoeia). These define minimum purity standards, test methods, and limits for heavy metals, arsenic, and other contaminants.
Rajindra’s pharmaceutical grades carry BP/USP test reports with every batch. The Certificate of Analysis documents results against pharmacopoeial methods — not just internal tests.
Why acid-washing is mandatory for injectables
Activated carbon, as produced, is mildly acidic — because of residual organic acids from the activation process. Standard carbon in contact with an aqueous pharmaceutical solution will lower the solution’s pH. For oral medications, this is typically acceptable. For injectable preparations, it is not.
Acid-washed carbon undergoes a controlled washing process that removes surface acidic groups, adjusting the carbon to near-neutral pH (typically 6.5–7.5). This ensures that the carbon, when added to an injectable API solution, does not alter the pH of the product.
What happens when you use the wrong carbon
Using standard (non-acid-washed) carbon in an injectable manufacturing process will cause pH drift in the API solution. This can affect the stability of pH-sensitive APIs, compromise the decolorisation step, and fail pharmacopoeial pH tests. Batch failures at this stage are expensive — the API is often the highest-cost input.